Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial

Background Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin. Methods In this...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Korean Diabetes Association 2023-11-01
Serie:	Diabetes & Metabolism Journal
Soggetti:	dapagliflozin diabetes mellitus, type 2 hypoglycemic agents metformin randomized controlled trial sodium-glucose transporter 2 inhibitors
Accesso online:	http://www.e-dmj.org/upload/pdf/dmj-2022-0315.pdf
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!